OCUL - These Analysts Boost Their Forecasts On Ocular Therapeutix After Q4 Results | Benzinga
Ocular Therapeutix, Inc. (NASDAQ: OCUL) reported worse-than-expected fourth-quarter financial results on Monday.
Ocular Therapeutix posted GAAP loss of 35 cents per share, compared to market estimates for a loss of 30 cents per share. The company’s quarterly sales came in at $14.802 million versus expectations of $15.707 million, according to data from Benzinga Pro.
Pravin Dugel, MD, Executive Chairman of Ocular Therapeutix said, "I believe the Company has made outstanding progress over the last several months, with the initiation of the Phase 3 SOL-1 study with AXPAXLI in wet AMD and successful financings that ...